Evidence map›Paper›PMID 41550956›Full record

ArticleFrontiers in immunology2025

The immunomodulating effect of palmitoylethanolamide on human myeloid dendritic cells and its possible impact on Alzheimer's disease.

Iliana Piccolino, Filomena Iannuzzi, Ludovica Lionetti, Benedetta Mazzonello, Valeria Barreca, Nerisa Banaj, Valentina Arezzini, Fabrizio Piras, Paola Bossù

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Palmitoylethanolamide in Human and Animal Obesity.Molecules (Basel, Switzerland) · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Iliana PiccolinoLaboratory of Experimental Neuropsychobiology, Scientific Institute for Research, Hospitalization, and Healthcare (IRCCS) Santa Lucia Foundation, Rome, Italy.
Filomena IannuzziLaboratory of Experimental Neuropsychobiology, Scientific Institute for Research, Hospitalization, and Healthcare (IRCCS) Santa Lucia Foundation, Rome, Italy.
Ludovica LionettiLaboratory of Experimental Neuropsychobiology, Scientific Institute for Research, Hospitalization, and Healthcare (IRCCS) Santa Lucia Foundation, Rome, Italy.
Benedetta MazzonelloLaboratory of Experimental Neuropsychobiology, Scientific Institute for Research, Hospitalization, and Healthcare (IRCCS) Santa Lucia Foundation, Rome, Italy.
Valeria BarrecaNational Center for Global Health, Istituto Superiore di Sanità, Rome, Italy.
Nerisa BanajLaboratory of Neuropsychiatry, IRCCS Santa Lucia Foundation, Rome, Italy.
Valentina ArezziniLaboratory of Neuropsychiatry, IRCCS Santa Lucia Foundation, Rome, Italy.
Fabrizio PirasLaboratory of Neuropsychiatry, IRCCS Santa Lucia Foundation, Rome, Italy.
Paola BossùLaboratory of Experimental Neuropsychobiology, Scientific Institute for Research, Hospitalization, and Healthcare (IRCCS) Santa Lucia Foundation, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Palmitoylethanolamide (PEA) is an endogenous fatty acid amide that has emerged as a promising therapeutic candidate for neurodegenerative disorders, particularly Alzheimer's disease (AD). Recognized for its inherent anti-inflammatory, analgesic, immunomodulatory, and neuroprotective properties, PEA possesses a good potential as a novel treatment addressing neuroinflammation associated with neurodegeneration, even though its precise mechanisms of action remain to be fully understood. Dendritic cells (DCs) are specialized migratory innate immune cells that play a crucial role in initiating and regulating immune responses and inflammation in both the body and the brain. In AD, DCs display a dysfunctional, pro-inflammatory profile, suggesting their involvement in disease pathology and progression. To explore the therapeutic potential of PEA, this study investigated its effects

Indexed as

Alzheimer DiseaseAmidesDendritic CellsEthanolaminesImmunomodulating AgentsPalmitic AcidsCells, CulturedHumansAmidesEthanolaminesImmunomodulating AgentspalmidrolPalmitic AcidsAlzheimer’s diseaseDC immunobiologyimmunomodulationinflammationmonocyte-derived dendritic cells (MDDCs)neurodegenerative diseasespalmitoylethanolamide (PEA)

Identifiers

PMID41550956
PMCPMC12807896

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.